AI주식인사이트AI Stock Insight
C

선바이오

067370KOSDAQ

48.0 / 100

Reference Date: 2026-09-08

Financial Score19.5 / 40
News Sentiment12.5 / 25
Momentum6.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Slightly down 3.5% over the past month, with no recent news.

Company InformationBased on 2025 Annual Report

Business Overview

SunBio focuses on developing and selling PEG-filgrastim (a neutropenia treatment), MucoPEG (a xerostomia treatment), and artificial blood SBX, along with producing and selling PEG derivatives. PEG-filgrastim is under U.S. approval proceedings, while MucoPEG faces delays in U.S. market entry due to patent issues. The company is also advancing research on solid electrolytes for lithium-ion batteries and aims to enhance competitiveness through a new factory in Incheon.

Number of Employees

29people

Average Salary

51.9M KRW

Score Calculation Basis

Detailed Financial Score

PER
27.42Industry Average 15.001.5Point

1.8x industry avg (risky)

PBR
2.66Industry Average 1.200.0Point

2.2x industry avg (risky)

ROE
9.99Industry Average 8.004.0Point

In line with industry avg

Debt Ratio
35.91Industry Average 100.006.5Point

Half of industry avg (excellent)

Trend 2023~20257.5 / 10 points
Revenue Growth Rate
2.5 / 3

Avg ▲14.1% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲467.1% (2-year basis)

ROE Trend
2.0 / 4

Avg ROE 9.1% (declining, 3yr)

Detailed News Sentiment

0 totalPositive 0Neutral 0Negative 0

Detailed Momentum

52-week position3.0Point

52w lower range (39%)

Current 6,280Won52-week high 8,29052-week low 4,945
1-month return2.0Point

1m -3.53% (slight drop)

Volume trend1.0Point

Volume dry-up

Detailed Disclosure

2 totalPositive 0Neutral 2Negative 0
  • Neutral전환사채(해외전환사채포함)발행후만기전사채취득2026-09-07
  • Neutral반기보고서 (2026.06)2026-08-13